830 related articles for article (PubMed ID: 18707731)
41. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
[TBL] [Abstract][Full Text] [Related]
42. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
[TBL] [Abstract][Full Text] [Related]
43. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
44. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?
Choo R; Danjoux C; Morton G; Szumacher E; Sugar L; Gardner S; Kim M; Choo CM; Klotz L
Prostate; 2007 Nov; 67(15):1614-20. PubMed ID: 17823923
[TBL] [Abstract][Full Text] [Related]
45. Prostate cancer in Victoria in 1993: patterns of reported management.
Frydenberg M; Giles GG; Mameghan H; Thursfield VJ; Millar J; Wheelahan JB; Bolton DM; Syme RR
Med J Aust; 2000 Mar; 172(6):270-4. PubMed ID: 10860092
[TBL] [Abstract][Full Text] [Related]
46. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
Guzzo TJ; Levin BM; Lee R; Guo M; Chen Z; Whittington R; Tomaszewski J; Malkowicz SB
Urology; 2008 Apr; 71(4):723-7. PubMed ID: 18387401
[TBL] [Abstract][Full Text] [Related]
47. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
Reese AC; Landis P; Han M; Epstein JI; Carter HB
J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
[TBL] [Abstract][Full Text] [Related]
48. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
[TBL] [Abstract][Full Text] [Related]
49. Active surveillance for good risk prostate cancer: rationale, method, and results.
Klotz LH
Can J Urol; 2005 Jun; 12 Suppl 2():21-4. PubMed ID: 16018828
[TBL] [Abstract][Full Text] [Related]
50. Prognostic features in men who died of prostate cancer.
Thompson KE; Hernández J; Canby-Hagino ED; Troyer D; Thompson IM
J Urol; 2005 Aug; 174(2):553-6; discussion 556. PubMed ID: 16006890
[TBL] [Abstract][Full Text] [Related]
51. Active surveillance for prostate cancer: an Australian experience.
Ischia JJ; Pang CY; Tay YK; Suen CF; Aw HC; Frydenberg M
BJU Int; 2012 Apr; 109 Suppl 3():40-3. PubMed ID: 22458492
[TBL] [Abstract][Full Text] [Related]
52. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
53. Prostate cancer risk assessment program: a 10-year update of cancer detection.
Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
[TBL] [Abstract][Full Text] [Related]
54. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
[TBL] [Abstract][Full Text] [Related]
55. Pathological outcomes of candidates for active surveillance of prostate cancer.
Conti SL; Dall'era M; Fradet V; Cowan JE; Simko J; Carroll PR
J Urol; 2009 Apr; 181(4):1628-33; discussion 1633-4. PubMed ID: 19233388
[TBL] [Abstract][Full Text] [Related]
56. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
Descazeaud A; Peyromaure M; Salin A; Amsellem-Ouazana D; Flam T; Viellefond A; Debré B; Zerbib M
Eur Urol; 2008 Feb; 53(2):355-61. PubMed ID: 17611015
[TBL] [Abstract][Full Text] [Related]
57. Salvage prostate cryoablation: initial results from the cryo on-line data registry.
Pisters LL; Rewcastle JC; Donnelly BJ; Lugnani FM; Katz AE; Jones JS
J Urol; 2008 Aug; 180(2):559-63; discussion 563-4. PubMed ID: 18554664
[TBL] [Abstract][Full Text] [Related]
58. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.
Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M
Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964
[TBL] [Abstract][Full Text] [Related]
59. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
60. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Albertson PC
Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]